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metrial ablation, low intensity pulsed ultrasound (LIPUS) and negative pressure
wound therapy were investigated further, through interviews with country and
product experts. RESULTS: Hospital and ambulatory sales could not be separated
but some differences in total sales between countries were apparent. Where HTA
processes existed they appeared to slow down access to new technologies. Several
interviewees highlighted a lack of expertise on local purchasing groups where
decisions are often based upon in-year budget considerations which restrict access
to some cost effective technologies. Even where new technologies are found to be
cost effective, DRG based funding systems are insufficiently flexible to establish
new out-patient fee levels. Hospitals have no financial incentive to treat patients in
an out-patient setting if the procedure cost exceeds existing out-patient DRG fees.
This prevents innovative technologies from being used in the most appropriate
way and cost saving opportunities are missed. CONCLUSIONS: Health providers
need to demonstrate new technologies are cost effective before commissioners
agree funding outside DRG based fee systems. The negotiation process would be
more efficient if commissioners pooled expertise for reviewing cost-effectiveness
evidence and fed their conclusions directly to DRG code and Tariff setting author-
ities. New DRG codes and higher out-patient tariffs for cost effective technologies
that enable a switch to ambulatory care could incentivise hospitals to revise care
pathways. Benefits will include lower procedure costs than in-patient treatment or
improved outcomes for patients.
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OBJECTIVES: An increasingly high-profile policy initiative being driven by the De-
partment of Health (DoH), the Association of the British Pharmaceutical Industry
(ABPI) and National Health Service (NHS) stakeholders, “joint working” encom-
passes a variety of forms of collaboration between the industry and the NHS in the
UK (UK). This study sought to characterise the current landscape for joint working
in the UK by surveying the types of projects being undertaken by participants.
METHODS: Secondary research was conducted to establish a comprehensive list of
joint-working projects; the websites of major pharmaceutical companies, the ABPI,
the DoH and other NHS stakeholders were surveyed for any references to joint
working. A classification system was created to segment projects by type of
scheme, therapeutic area(s) and stakeholders involved. This segmentation was
analysed to look for qualitative trends in the UK joint-working environment.
RESULTS: A key finding of the study is that many pharmaceutical companies are
now active in joint working. Joint-working projects encompass a broad range of
therapeutic areas, with most companies active in areas in which they have assets.
These projects can be segmented into a number of different categories, including
those centered on service (re)design, service appraisals in light of current guide-
lines, and techniques to better manage or educate patients. Pharmaceutical com-
panies are also active in providing training or other types of support to health care
professionals and managers within the NHS. CONCLUSIONS: The joint-working
policy initiative in the UK has resulted in a significant number of partnerships
within the NHS in recent years. These projects are varied in nature, and have seen
the pharmaceutical industry and the health service cooperate in innovative ways.
Increasingly, companies are willing to share their expertise and resources in proj-
ects which have indirect benefits for them in terms of the market access of their
products.
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OBJECTIVES: To compare and explain current drug pricing systems in Bosnia and
Herzegovina (B&H) for reimbursed drugs by Health Insurance Funds (HIF) and out-
of-pocket drugs. METHODS: Analysis of reimbursement list and legislation on ac-
ces to drugs in B&H is performed. We analysed pricing for reimbursed drugs and
out-of-pocket drug prices regulation and explain cost structure. RESULTS: General
drug pricing system is set by Agency for medicines and medical devices of B&H.
Prices are defined as maximal wholeseler price (WSP) and pricing is based on re-
feral pricing. Referal countries are Croatia, Serbia, Slovenia, Austria and Italy. B&H
price must be set at level of referal price with addoption for patented drug (100%),
originator (95%) and generics (90%). Prices are revised each year and published on
Agency website. Maximal wholeseler margine is up to 8%, while retail margine is
set by entity laws. In Federation maximal retail margine is 25% while in Republic of
Srpska margine is fixed on 20% add on WSP. Reimbursable price in Republic of
Srpska is defined as lowest offered price for each INN and presentation. Price dif-
ference can be paid by patient depenting on preferences. Reimbursed prices for
drugs included into Federal reimbursement list is set by nagotiation process with
manufacturers. All prices should be revised and adopted annualy to the Agency
published prices. Retail margine is not applicable for reimbursed drugs because
pharmacy is paid by HIF per prescription according to the agreement.
CONCLUSIONS: Even there is intention to unify pharmaceutical market and drug
prices in Bosnia and Herzegovine, there are still differences in price and related
pricing regulations. Recently published Rule on price control by state Agency
should contribute to equalisation of prices in Bosnia and Herzegovina.
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OBJECTIVES: In 2006 a law for the economical use of medications was introduced
into the Hungarian legislation. This law – among others – facilitated the foundation
of new pharmacies. The aim of our study is to analyse the effect of that legislation
on the annual turnover of community pharmacies. METHODS: Data were derived
from the pharmaceutical database of the Hungarian Health Insurance Fund Ad-
ministration (OEP), the only health care financing agency in Hungary. We analysed
the 5 years period between 2006-2010. The main indicator of our analyses was the
annual turnover of pharmacies calculated on health insurance reimbursement
according to the number of population of different settlements. RESULTS: The
average annual turnover – calculated on health insurance reimbursement – of a
community pharmacy was 176.8 million Hungarian Forint (HUF) or 669011 EUR in
2006 with significant differences according to the size of population. Pharmacies
located in small cities had a much lower average annual turnover (0-499 popula-
tion: 105.6 million HUF; 500-999: 41.9 million HUF; 1000-1999: 63.2 million HUF),
while the turnover of pharmacies located in bigger cities, was significantly higher
(10000-49999 population: 217.6 million HUF; 50000-99999: 231.9 million HUF; over
100000: 241.6 million HUF). The average annual turnover of a community pharmacy
was 135.4 million Hungarian Forint (HUF) or 491627 EUR in 2010, i.e. 76.6 % of 2006’s
turnover. Between 2006 and 2010, the annual turnover of pharmacies in small
villages (population 0-1999) varied between 86.1-103.7 % while those of big cities
(population over 10000) changed to 66.9-76.5 %. CONCLUSIONS: The annual turn-
over of pharmacies in small villages was significantly lower than those of big towns
during the study period 2006-2010. However, the annual turnover of small villages’
pharmacies decreased moderately compared to pharmacies located in bigger
towns because new pharmacies were established in bigger towns.
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OBJECTIVES: In an attempt to assess time to market and price levels of innovative
drugs, we surveyed market availability and drug prices for a basket of drugs in the
top 5 European pharmaceutical markets.METHODS: The market availability of 125
innovative drugs – approved between July 2009 and April 2012 by the European
Medicines Agency – in France, Germany, Italy, Spain, and the United-Kingdom was
analysed. Within this sample, prices of 10 drugs marketed in each of the market
studied were compared. RESULTS: Most of the drugs included in our sample are
marketed in Germany and the UK, 59% and 54% respectively. In Spain, France and
Italy this figure drops to 39%, 33%, and 32% respectively. It should be highlighted
that only 14% of the drugs was available in all the markets analysed. Prices are
commonly the highest in Germany and lower in Italy or the UK. Additionally, while
for an identical drug, most examples show significant price differences between
the markets studied, a few showed that the price corridor was relatively narrow.
CONCLUSIONS:Our results show that Germany and the UK – where prices have not
been directly controlled – are still prioritised, while market entry occurs at a later
stage in France, Italy and Spain. The fact that large price differences are still ob-
served between countries means that there is still flexibility in terms of pricing
strategies. The pricing procedure implemented in 2011 in Germany, has not had an
immediate impact on prices - which are still the highest. However, an impact is
already being felt on market access. Several innovative drugs were not launched in
Germany when the price outcome was expected to be unsuccessful.
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OBJECTIVES: Drug manufacturers, facing patent protection termination, have de-
veloped strategies to maintain market share. These include marketing evergreen-
ing drugs (slow release formulations, single isomer chiral molecules, or structural
analogues/combinations of original patented drugs) and offering high rebates to
hospitals that use brand-name or evergreening drugs. Our objective was to assess
the financial impact of evergreening drug prescriptions in the community, and to
measure the impact of a hospital restrictive drug formulary (RDF) on health care
expenditures. METHODS: We combined three administrative registries from the
canton of Geneva, Switzerland to analyse all prescriptions between January 2000
and December 2008. We developed cost-minimisation models calculating ever-
greening and brand drug prescriptions at their corresponding generic selling price
equivalents. ARIMA models measured the spillover effect of hospital prescription
patterns into the community. Spillover costs were compared to hospital savings.
Summary results were aggregated on a yearly basis and extrapolated to the canton
of Geneva. RESULTS: Evergreening drug prescriptions resulted in an extra cost of
€20,172,000 over the study period. Brand drug extra costs decreased from €6,555,000
(2004) to €1,403,000 (2008), but were offset by the increase in evergreening drug
prescriptions (“squeezing the balloon” phenomenon). The final extra cost to the
health care system was €42,147,000. The use of a hospital RDF to control cost
resulted in global savings of €837,000. However, listing drugs on the hospital RDF
decreased health care system savings to €31,000 only due to increased prescription
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